Literature DB >> 12189219

FDA evaluating oxaliplatin for advanced colorectal cancer treatment.

Joyce Baldwin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12189219     DOI： 10.1093/jnci/94.16.1191

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  3 in total

1.  Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

Authors:  H Sayar; Z Shen; S J Lee; M Royce; I Rabinowitz; F Lee; H Smith; S Eberhardt; A Maestas; H Lu; C Verschraegen
Journal:  Invest New Drugs       Date:  2008-09-05       Impact factor: 3.850

2.  Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy.

Authors:  Tamana Walia; J Fernando Quevedo; Timothy J Hobday; Gary Croghan; Aminah Jatoi
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

3.  Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.

Authors:  A Guglielmi; S Barni; A Zaniboni; N Pella; O Belvedere; G D Beretta; F Grossi; L Frontini; F Puglisi; R Labianca; A Sobrero
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.